Eli Lilly's Alzheimer's Drug Shows Greatest Benefit Yet
In a May 3 press release, Eli Lilly announced encouraging results from its latest study of its Alzheimer's drug candidate, donanemab.In the Phase 3 study, which included more than 1,000 people with early signs of Alzheimer's disease, people receiving donanemab experienced 35% slower cognitive decline, as measured on cognitive tests, than people receiving placebo.